196 related articles for article (PubMed ID: 26287334)
1. Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer.
Cao H; Dong W; Shen H; Xu J; Zhu L; Liu Q; Du J
PLoS One; 2015; 10(8):e0135844. PubMed ID: 26287334
[TBL] [Abstract][Full Text] [Related]
2. Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC.
Cao H; Dong W; Qu X; Shen H; Xu J; Zhu L; Liu Q; Du J
Sci Rep; 2016 Aug; 6():31072. PubMed ID: 27488947
[TBL] [Abstract][Full Text] [Related]
3. β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.
Zheng H; Shen H; Oprea I; Worrall C; Stefanescu R; Girnita A; Girnita L
Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20620-5. PubMed ID: 23188799
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma.
Zhang T; Shen H; Dong W; Qu X; Liu Q; Du J
Sci Rep; 2014 Oct; 4():6855. PubMed ID: 25358597
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
[TBL] [Abstract][Full Text] [Related]
6. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy.
Ferté C; Loriot Y; Clémenson C; Commo F; Gombos A; Bibault JE; Fumagalli I; Hamama S; Auger N; Lahon B; Chargari C; Calderaro J; Soria JC; Deutsch E
Mol Cancer Ther; 2013 Jul; 12(7):1213-22. PubMed ID: 23640142
[TBL] [Abstract][Full Text] [Related]
7. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
Bertrand FE; Steelman LS; Chappell WH; Abrams SL; Shelton JG; White ER; Ludwig DL; McCubrey JA
Leukemia; 2006 Jul; 20(7):1254-60. PubMed ID: 16642049
[TBL] [Abstract][Full Text] [Related]
8. ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer.
Zinn RL; Gardner EE; Marchionni L; Murphy SC; Dobromilskaya I; Hann CL; Rudin CM
Mol Cancer Ther; 2013 Jun; 12(6):1131-9. PubMed ID: 23515613
[TBL] [Abstract][Full Text] [Related]
9. Phosphoprotein analysis reveals MEK inhibition as a way to target non-small cell lung cancer tumor initiating cells.
Lundholm L; Hååg P; Juntti T; Lewensohn R; Viktorsson K
Int J Radiat Biol; 2014 Aug; 90(8):718-26. PubMed ID: 24646078
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
11. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.
Chapuis N; Tamburini J; Cornillet-Lefebvre P; Gillot L; Bardet V; Willems L; Park S; Green AS; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Haematologica; 2010 Mar; 95(3):415-23. PubMed ID: 20007139
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
13. Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.
Shin DH; Lee HJ; Min HY; Choi SP; Lee MS; Lee JW; Johnson FM; Mehta K; Lippman SM; Glisson BS; Lee HY
J Natl Cancer Inst; 2013 Oct; 105(20):1558-70. PubMed ID: 24092920
[TBL] [Abstract][Full Text] [Related]
14. A role for IGF-1R-targeted therapies in small-cell lung cancer?
Gately K; Collins I; Forde L; Al-Alao B; Young V; Gerg M; Feuerhake F; O'Byrne K
Clin Lung Cancer; 2011 Jan; 12(1):38-42. PubMed ID: 21273178
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor.
Davaadelger B; Duan L; Perez RE; Gitelis S; Maki CG
Oncotarget; 2016 May; 7(19):27511-26. PubMed ID: 27050276
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of microRNA-223 promotes degranulation via the PI3K/Akt pathway by targeting IGF-1R in mast cells.
Wang Q; Zhao DY; Xu H; Zhou H; Yang QY; Liu F; Zhou GP
PLoS One; 2015; 10(4):e0123575. PubMed ID: 25875646
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
Suyama H; Igishi T; Ueda Y; Shigeoka Y; Kodani M; Morita M; Takeda K; Sumikawa T; Nakazaki H; Matsunami K; Matsumoto S; Shimizu E
Oncol Rep; 2010 Jan; 23(1):217-22. PubMed ID: 19956885
[TBL] [Abstract][Full Text] [Related]
18. Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor.
Girnita A; Zheng H; Grönberg A; Girnita L; Ståhle M
Oncogene; 2012 Jan; 31(3):352-65. PubMed ID: 21685939
[TBL] [Abstract][Full Text] [Related]
19. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells.
Ma J; Sawai H; Matsuo Y; Ochi N; Yasuda A; Takahashi H; Wakasugi T; Funahashi H; Sato M; Takeyama H
J Surg Res; 2010 May; 160(1):90-101. PubMed ID: 19560785
[TBL] [Abstract][Full Text] [Related]
20. Functional antagonism of β-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes.
Suleymanova N; Crudden C; Shibano T; Worrall C; Oprea I; Tica A; Calin GA; Girnita A; Girnita L
Oncogene; 2017 Oct; 36(41):5734-5744. PubMed ID: 28581517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
